Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
Friday, January 11, 2013 - 11:30
in Health & Medicine
"Not only do we see more abnormal methylation in non-Hodgkin lymphoma patients than in healthy B-cell populations, but there are three distinct subtypes of the disease in the clinic, each more aggressive than the next. These three clinical trajectories of non-Hodgkins lymphoma were distinctly marked by their levels of abnormal methylation," says a CU Cancer Center investigator.